DUBLIN – Astrazeneca could garner as much as $400 million from a deal with Takeda Pharmaceutical Co. Ltd. to co-develop its preclinical alpha-synuclein-targeting antibody, MEDI-1341, which is slated to enter clinical development in Parkinson's disease before year-end.